A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters
Article in Vaccine (October 2024)
The most recent citing publications are shown below. View all 46 publications that cite this research output on Dimensions.
TOLL-LIKE RECEPTORS AND BRONCHIAL ASTHMA: PART 2
Article in Transbaikalian Medical Bulletin (July 2024)
Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity
Article in Virology (March 2024)